BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Animal Cell Therapies Announces Cell Inventory Value at $6 Million


3/15/2012 10:23:56 AM

SAN DIEGO – February 13, 2012 – Animal Cell Therapies (ACT), a company specializing in veterinary diagnostics and cell-based therapies, today announced that its stem cell inventory is valued at more than $6 million. The evaluation, conducted by Cheetahlink and Capital Consulting Services, demonstrates the importance of this first step in the company’s mission to improve and extend the lives of dogs through innovative stem cell products and services.

When Animal Cell Therapies was created, the company partnered with a select group of researchers, scientists and collaborators from the U.S. and abroad to create an in-house program to grow and expand well-characterized animal stem cells in a scientific setting. The company’s founder, Dr. Kathryn Petrucci, recognized that in order to provide pure, potent, reliable, pathogen-free animal stem cells, ACT must optimize stem cell storage while improving stem cell transportation procedures and delivery techniques.

“This valuation essentially validates that the foundation we’ve set for this company – in the creation and maintaining of this stem cell inventory – is sound and will support the next steps in our strategy,” said Adam Irving, chief executive officer of Animal Cell Therapies. “Our capabilities are far reaching with broad applications.”

In maintaining its stem cell inventory, Animal Cell Therapies conducts specific cell assays, characterization processes and procedures to assess potential toxicity and consistently assure safety, purity, potency and a stable finished stem cell product or stem cell derivative. In addition, Animal Cell Therapies monitors processes with standardized, rigorous quality control specifications and testing parameters.

About Animal Cell Therapies

Founded in January 2008 in San Diego, California, Animal Cell Therapies (ACT) is the manifestation of veterinarian, Dr. Kathryn Petrucci, whose vision is to improve the lives of animals through thoughtful research and development, innovation and strategic partnerships. At the Company’s California-based stem cell research and development facility, the ACT team is focused on developing and delivering revolutionary cellular treatment and services to their customers. For more information, visit www.actcells.com.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES